Background: The aim of this study was to estimate separate risks of major lower limb amputation and death following revascularization for peripheral artery disease (PAD) using competing risks analysis. 
Introduction
Peripheral artery disease (PAD), characterized by atherosclerotic obstruction to blood flow in the arteries of the lower limbs, is the third most common cause of morbidity worldwide, after stroke and coronary heart disease 1 . The prevalence of PAD is growing; in 2010, an estimated 61 million men and women in high-income countries were living with this disease, representing a 13 per cent increase during the preceding decade 1 . An important treatment goal in PAD is to manage blood flow to the limb. Where medical treatment or lifestyle modification has been inadequate, endovascular and open revascularization procedures can be used to improve blood flow. These interventions carry appreciable risks to life and limb 2, 3 . The BASIL (Bypass versus Angioplasty in Severe Ischaemia of the Limb) RCT 2 , which recruited patients between 1999 and 2004, reported 3-year amputation-free survival rates of 57 per cent among patients randomized to bypass and 52 per cent among those randomized to angioplasty. Studies from registries in the USA 4 and Sweden 5 between 1996 and 2003 reported similar findings, with 5-year amputation-free survival rates of just under 50 per cent following leg bypass.
Previous studies 2 -6 of patient outcomes following lower limb revascularization have reported on death or amputation-free survival (time to death or major lower limb amputation, whichever occurs first). Few investigations have provided information on the risk of amputation independently of the risk of death, although this is an important outcome for patients. In studies that have reported separate amputation rates 4,7 -9 , time to amputation has typically been derived using standard Kaplan-Meier analysis and Cox proportional hazards regression. These methods are based on the assumption that the risks of multiple outcomes are independent, and they will produce biased estimates in the presence of non-independent competing risks 10, 11 . The independent risks assumption is unlikely to be valid in a population of patients undergoing revascularization for PAD. In this group of typically older patients with high levels of multiple morbidity, rates of both death and amputation are relatively high, and the rate of amputation is influenced by the rate of death. This is because patients who have died are no longer at risk of having an amputation, and the risks of amputation and death are therefore not independent of one another. It is thus likely that many previously published estimates of the risk of amputation following lower limb revascularization have been overestimated by standard methods.
The aim of the present investigation was to examine the separate risks of major lower limb amputation and death following lower limb revascularization for PAD in England using a competing risks approach 12 .
Methods
Individual-level data were used to identify all lower limb revascularization procedures for PAD recorded in Hospital Episode Statistics (HES), an administrative data set containing information on all hospital admissions in National Health Service (NHS) hospitals in England 13 . Patient HES records include information on procedures, patient characteristics and admission details. Medical diagnoses are coded using ICD-10 and procedures using OPCS-4 codes. In the analyses described here, each patient was identified using an anonymized label, which allowed all of their admissions data to be linked. Patient deaths were ascertained from Office for National Statistics records of deaths registered in England up to December 2015 14 . The study was exempt from UK National Research Ethics Committee approval as it involved secondary analysis of an existing data set of anonymized data. HES data were made available by NHS Digital (©2015, reused with the permission of NHS Digital. All rights reserved).
Study population
The study population included men and women, aged 35 years or older, who underwent their first lower limb revascularization for PAD (index procedure) between 1 January 2005 and 31 December 2015. Patients who had a HES record of lower limb revascularization up to 3 years before the index procedure were excluded. Also excluded were non-UK residents, patients whose primary indication for revascularization was malignant or benign neoplastic disease, trauma or congenital malformation, and those with incomplete data on co-variates (less than 0⋅01 per cent).
Revascularization procedures were grouped into three categories: endovascular revascularization alone, open revascularization (endarterectomy, profundaplasty or bypass) alone, or a combination of endovascular and open procedures. Primary and secondary diagnostic codes at the index admission were used to identify patients undergoing these procedures for PAD. Patients were grouped according to increasing severity of PAD as follows: intermittent claudication (IC group; ICD-10 code I73.9), severe limb ischaemia without a record of tissue loss (SLI group; ICD-10 code(s) I70.2, I72.4, I70.0-8, I74.3-5, I77.1 or I77.9, but no code(s) for diabetes with peripheral circulatory complications or tissue loss) and severe limb ischaemia with a record of tissue loss (TL group; code(s) for PAD and code(s) indicating tissue loss or diabetes with peripheral circulatory complications) (Tables S1-S3, supporting information).
The risk estimates were adjusted for patient age, sex and Royal College of Surgeons Charlson score, which was derived using primary and secondary diagnostic codes from the index hospital admission as well as admissions during the 12 months preceding the index admission 15 . Acute conditions (such as myocardial infarction) were included in the number of co-morbidities only if they were present in a record of a hospital admission preceding the index admission (Table S4 , supporting information). PAD and diabetes were excluded from calculation of the co-morbidity score because these formed part of the inclusion criteria for the study, and all patients had a record of at least one of these.
Outcomes
The primary outcomes were major lower limb (above the ankle) amputation (ipsilateral or contralateral) and death from any cause, on a date later than the date of the revascularization procedure. Amputations resulting from trauma or neoplastic disease were excluded. Amputation-free survival (time from revascularization procedure to major amputation, death from any cause or the end of follow-up, whichever occurred first) was examined as a secondary outcome. OPCS codes for identifying major lower limb amputations are provided in Table S5 (supporting information).
Statistical analysis
Patients were followed up from the date of the revascularization to the date of a subsequent major lower limb amputation, death or the end of follow-up (December 2015), for a maximum of 5 years. The cumulative incidences of major amputation and death, independent of one another, were estimated for each type of revascularization and indication for treatment using Fine-Gray competing risks regression models 12 . The competing risks approach was chosen because, in the presence of non-independent competing risks, the cumulative incidence of an outcome (such as major amputation) is influenced by the cumulative incidence(s) of competing outcome(s) (such as death) 10, 11 . The Fine-Gray model overcomes this problem by producing separate estimates for the cumulative incidence of the main outcome and the competing outcome 12 . Using the competing risks approach, amputation-free survival was calculated as 1 minus the sum of the independent cumulative incidences of amputation and death.
Three sensitivity analyses were conducted: the first used Kaplan-Meier curves and Cox proportional hazards regression 16 to illustrate the degree to which the risk of amputation was overestimated using standard survival analysis methods; the second examined the impact of not adjusting for RCS Charlson score in the competing risks models; and the third investigated the effect of combining severe limb ischaemia with no tissue loss and severe limb ischaemia with tissue loss as one analytical category. The latter two analyses were done to explore the impact of the quality of coding for secondary diagnoses and co-morbidities in HES.
The proportional hazards assumption for the Cox models was checked visually, using log-log plots (log-log of the survival function against the logarithm of time) and the Schoenfeld test (testing for interaction between Schoenfeld residuals and time). In the competing risk models, the proportionality of subdistribution hazards was checked by including an interaction term with time in the model. The assumptions were reasonably valid for all procedure-outcome pairs. Age (10-year bands from 30 to over 80 years), sex, RCS Charlson score (0, 1, 2, 3 or more) and indication for revascularization (IC, SLI or TL group) were modelled as categorical variables. All analyses were conducted using Stata ® MP 14 (StataCorp, College Station, Texas, USA).
Results
Some 164 845 men and women underwent their first lower limb revascularization for PAD. Overall, the majority were men (64⋅6 per cent) and median age was 71 (i.q.r. 62-78) years. The most common procedure Severe limb ischaemia without a record of tissue loss (SLI group) was the most common indication for endovascular revascularization, recorded as the underlying aetiology in 55⋅6 per cent of all revascularization procedures. IC was the indication for 22⋅9 per cent of patients in all procedure groups, and severe limb ischaemia with a record of tissue loss (TL group) accounted for 21⋅6 per cent ( Table 1) . Overall, 85⋅7 per cent of patients had at least one co-morbidity indicated by the RCS Charlson score, and 22⋅0 per cent had three or more.
Some 13 620 patients (8⋅3 per cent) had a major lower limb amputation and 42 570 (25⋅8 per cent) died during the 5 years following lower limb revascularization. Median follow-up was 3 (i.q.r. 1-5 years). Unadjusted estimates of cumulative incidence of major lower limb amputations associated with each type of revascularization were calculated using Kaplan-Meier and Fine-Gray methods (Fig. 1) . The Kaplan-Meier method consistently produced higher estimates of the risk of amputation, particularly with longer follow-up.
The unadjusted cumulative incidence of amputation and death at 1, 3 and 5 years after revascularization was calculated for each procedure and indication using the competing risks approach ( Table 2 ). The cumulative incidence of major lower limb amputation was higher in patients undergoing open revascularization than in those having endovascular procedures. It was also notably higher in patients who underwent revascularization for severe limb ischaemia with a record of tissue loss (TL group) than in patients whose indication for revascularization was IC or severe limb ischaemia without a record of tissue loss (SLI group) ( Table 2 ). The cumulative incidence of death was relatively high in all patient groups.
Amputation-free survival at 5 years varied by procedure type and indication. It was lowest (26⋅1 per cent) in those who underwent endovascular revascularization for tissue loss and highest (71⋅1 per cent) among those who had endovascular procedures for IC ( Table 3) . Amputation-free survival at 5 years following open and combined procedures showed similar patterns. Of patients who underwent open or combined revascularization for tissue loss, about 30 per cent survived free from major lower limb amputation at 5 years after revascularization. Of patients who underwent these procedures for IC, some 60 per cent survived to 5 years without a major amputation. Table 4 ). Overall, the cumulative incidence of both outcomes increased sharply over the first year after revascularization in all procedure and indication groups; the increase continued in the following years, at a steady but lower rate. At 5 years after revascularization, the adjusted cumulative incidence of amputation was lowest among patients undergoing endovascular procedures for IC (4⋅2 per cent) and highest Table 2 Unadjusted cumulative incidence of major amputation and death after lower limb revascularization, by procedure and indication Cumulative incidence of amputation (%)
Cumulative incidence of death (%) Values in parentheses are percentages. IC, intermittent claudication; SLI, severe limb ischaemia without a record of tissue loss; TL, severe limb ischaemia with a record of tissue loss. among those having open revascularization for tissue loss (25⋅3 per cent). When estimated independently of the cumulative incidence of amputation and adjusted for patient characteristics, the cumulative incidence of death was relatively high in all patient groups. Regardless of the indication for intervention, between 24⋅5 and 39⋅8 per cent of patients died within 5 years of the revascularization procedure ( Figs 2-4 and Table 4 ).
The results of sensitivity analyses exploring the potential impact of the quality of diagnostic coding suggested that the main findings of the study were reasonably robust. The results from the analyses without adjustment for RCS Charlson score were nearly identical to the main findings ( Figs S1-S3, supporting information) , reflecting the fact that the burden of co-morbidity was similar across the indication categories. The risk of amputation in the combined SLI + TL group was higher than that in the SLI group, as might be expected, but the difference was relatively modest (Table 2) . Similarly, amputation-free survival was somewhat lower in the SLI + TL group than in the SLI group (Table 3) . These observations suggest that, although misclassification of patients as having severe limb ischaemia alone when in reality they also had tissue loss (as suggested by the large proportion of patients in the SLI group) would inflate the risk estimates for the SLI group, the influence of such bias on the main findings was likely to be small. The sensitivity analysis comparing the two analytical approaches demonstrated that the risks of both amputation and death estimated using Kaplan-Meier methods were higher than those estimated using the competing risks methods, particularly among patients with a record of tissue loss ( Figs S1-S3 , supporting information). 
*Adjusted for patient age, sex and Royal College of Surgeons Charlson score. IC, intermittent claudication; SLI, severe limb ischaemia without a record of tissue loss; TL, severe limb ischaemia with a record of tissue loss.
Discussion
The competing risks approach consistently produced lower estimates of the cumulative incidence of both outcomes than standard survival analysis methods, particularly towards the end of the 5-year follow-up and for patients with the most severe PAD (TL group).
Findings from previous studies 2 -5 in England, Sweden and the USA suggested that the overall 5-year rates of major lower limb amputation following open and endovascular revascularization lie between 40 and 50 per cent. The present findings indicated that the risk of amputation following revascularization for PAD is lower; the highest risks of major lower limb amputation, some 25 per cent, were observed in patients undergoing open procedures, either alone or in combination with endovascular revascularization, for the most severe underlying disease (TL group). By contrast, the 5-year risk of amputation was lowest among patients who underwent endovascular revascularization for IC or severe limb ischaemia (4⋅2 and 6⋅5 per cent respectively). The differences between the present observations and those of previous studies are likely to relate to standard survival analysis (Kaplan-Meier and Cox) methods overestimating the risk of amputation in this patient population, where the risks of amputation and death are not independent of one another, and where most patients have a high risk of death from old age and multiple co-morbidities. The amputation-free survival rate at 5 years after revascularization, calculated using competing risks methods, ranged from 26⋅1 to 71⋅1 per cent following endovascular procedures, and from 29⋅8 to 60⋅2 per cent after open procedures (either alone or in combination with endovascular revascularization). However, the outcomes following endovascular and surgical revascularization are encouraging compared with those of conservative treatment for limb ischaemia. Estimates from a recent meta-analysis 17 suggested that over 40 per cent of the patients receiving conservative treatment had lost a limb and about 25 per cent had died by 1-year follow-up.
Overall risk estimates can mask meaningful differences in the risks of outcomes between patients with different severity of underlying disease. The findings of a longitudinal analysis 9 of public health insurance data from over 41 000 German men and women suggested that the 4-year risks of amputation and death vary considerably according to disease severity, ranging from 4⋅6 per cent in Rutherford category 1 to 67⋅3 per cent in Rutherford category 6. The present observations were similar in direction but smaller in magnitude; the 5-year risk of major lower limb amputation varied from 4⋅2 per cent in patients undergoing endovascular revascularization for IC (the least severe disease) to 25⋅3 per cent in those undergoing open repair for tissue loss (the most severe PAD). Again, one explanation for the discrepancies in the results is likely to be standard survival methods overestimating risks. However, it must be noted that the findings presented here may not be directly comparable to those from other countries, because the ICD-10 codes in HES data do not allow a conclusive distinction to be made between categories indicating the severity of PAD. Consequently, the risk estimates relating to the IC, SLI and TL groups in the present analyses should be taken as indicative of typical risks in such groups in England, and not be used directly in international comparisons.
An important strength of the present investigation is the use of a competing risks approach, which allows estimation of the risks of amputation and death separately from one another, thus providing accurate estimates of these risks. Furthermore, the analyses were based on prospectively collected individual-patient data on all revascularizations in English NHS hospitals in 2005-2015. Therefore, it is unlikely that the findings have been biased by sample selection or loss to follow-up. Based on data from just under 165 000 patients, the analyses are likely to have sufficient statistical power to provide precise estimates of the risk of amputation following endovascular and open revascularization procedures in England.
Despite the strengths of large data sets, analyses based on administrative hospital data, such as HES, are prone to biases arising from incomplete or inaccurate clinical coding. A systematic review 18 of the quality of HES data suggested that the accuracy of diagnostic coding was less than satisfactory until the mid to late 2000s, but that it has improved since. However, although many primary diagnoses and procedures related to cardiovascular disease are coded reasonably accurately 19 , there is evidence that the quality of coding for subsequent diagnoses and procedures varies between hospitals 20 . It is therefore possible that the present findings have been influenced by differential omission of secondary diagnostic codes and the lack of consistency in coding PAD symptoms using ICD-10. To minimize the effect of coding errors, a wide range of codes was used to capture as many disease events as possible for the purposes of defining the severity of PAD and identifying co-morbidities. However, the severity of the underlying PAD and the number of co-morbidities (which was based on secondary diagnostic codes) may have been underascertained if coding of secondary diagnoses was incomplete or inaccurate. Misclassifying patients as having fewer co-morbidities than they actually had could dilute the cumulative incidence estimates by introducing error (statistical 'noise'). Similarly, misclassifying more severely ill patients into less severely ill categories could lead to overestimation of the risks of amputation and death for the less severe indication. However, the sensitivity analyses suggested that the potential bias this might have introduced to the SLI group was small. Misclassification in co-variables would also reduce the ability to adjust for these 21 . Analyses based on better-quality data for patient-level risk factors would help to gauge the extent and impact of these potential biases in administrative data.
It was not possible to ascertain reliably the laterality of the amputations based on HES data, and it is therefore not known what proportion of amputations were done on the same leg as the revascularization. However, in terms of providing information that is relevant to patients, this is not a major limitation, as patients tend to be concerned about their overall risk of losing a limb after revascularization, rather than specific risks of losing the ipsilateral or contralateral limb.
Finally, although HES is a rich source of data on hospital admissions and procedures, it does not contain information on patient-level physiological or lifestyle factors, which may influence the risk of amputation or death following lower limb revascularization. For this reason, it was not possible to investigate the potential impact of factors such as smoking, control of BP or diabetes, or physical activity on the present findings. These are areas for future research.
The findings of this analysis support those of previous studies that standard survival methods of analysis can overestimate the risk of the primary outcome of interest in the presence of a competing outcome 11 . This highlights the importance of using appropriate statistical methods to estimate the risk of amputation in the population undergoing revascularization, as most of these patients are at high of death from old age and multiple co-morbidities. Importantly, using the appropriate methodology allows accurate detection of variation in clinical outcomes, which is needed for planning of healthcare delivery and resource allocation in vascular surgery and other areas.
